Emricasan is an effective and irreversible pan-caspase inhibitor.
Emricasan (IDN-6556 or PF-03491390) is an inhibitor of activated caspases, and it has sub- to nanomolar activity in vitro. Emricasan has a neuroprotective activity for hNPCs but does not inhibit ZIKV replication.
Emricasan reduces liver injury but not metabolic derangement in NASH. It also ameliorates inflammation. In the murine NASH model, Emricasan can attenuate stellate cell activation and hepatic fibrogenesis.
Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference)